Ventracor Chief Executive Officer Peter Crosby spoke at the 19th Annual Piper Jaffray Global Health Care Conference on Tuesday 27 November in New York City.
Overall I was happy with the news. Here are some of the negatives and positives;
# Negative:
- cash burn is $2.6 mil / mth, but he said this figure will grow in fiscal yr 08 due to clinical trials being ramped up. However will then ramp down again as revenues increase.
# Positives:
- Opened up the 1st Asian Centre and they expect to implant very soon!!
- Cash bal end of Jun 07 was $48.5 mil(cashed up)
- Innovative US clinical trials which is subject to a Patent which was filed last year which will give VCR a competitive advantage with reference to enrolment / speed / FDA approval much sooner than it will take Thoratec to attain it.
- Implants of 300 to 400 by mid 08 !!!
VCR Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
